Compare GLBE & INDV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GLBE | INDV |
|---|---|---|
| Founded | 2013 | N/A |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1B | 4.4B |
| IPO Year | 2020 | 2014 |
| Metric | GLBE | INDV |
|---|---|---|
| Price | $38.49 | $40.50 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 12 | 0 |
| Target Price | ★ $47.08 | N/A |
| AVG Volume (30 Days) | ★ 1.7M | 1.6M |
| Earning Date | 05-13-2026 | 06-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 8100.00 |
| EPS | N/A | ★ 0.69 |
| Revenue | N/A | ★ $1,239,000,000.00 |
| Revenue This Year | $31.78 | N/A |
| Revenue Next Year | $24.45 | N/A |
| P/E Ratio | $89.26 | ★ $59.86 |
| Revenue Growth | N/A | ★ 4.29 |
| 52 Week Low | $26.85 | $15.00 |
| 52 Week High | $41.94 | $42.81 |
| Indicator | GLBE | INDV |
|---|---|---|
| Relative Strength Index (RSI) | 66.63 | 57.41 |
| Support Level | $37.78 | $35.36 |
| Resistance Level | $39.00 | $41.00 |
| Average True Range (ATR) | 1.78 | 1.56 |
| MACD | 0.30 | -0.06 |
| Stochastic Oscillator | 89.62 | 55.32 |
Global E Online Ltd provides e-commerce solutions. The company offers a platform to enable and accelerate direct-to-consumer cross-border e-commerce. The platform was purpose-built for international shoppers to buy seamlessly online and for merchants to sell from, and to, anywhere in the world. The company localizes the shopper experience to make international transactions as seamless as domestic ones. The platform increases the conversion of international traffic into sales by removing much of the complexity associated with international e-commerce. The company derives maximum revenue from the United States.
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).